John Kerr posted in hep c • hepatitis • personalised medicine • pharmac • pharmacogenomics on August 22nd, 2013.
PHARMAC has announced it will fund a new hepatitis C drug targeted to patients who carry a particular gene variant, highlighting the rise of personalised medicine. The government drug buying agency will begin funding boceprevir (Victrelis) from next month for certain patients for the treatment of hepatitis C in combination with other drugs. The treatment […]
Continue reading “PHARMAC funds genetically-targeted Hep C drug”